ArticleLeukemia2018

Saracatinib impairs maintenance of human T-ALL by targeting the LCK tyrosine kinase in cells displaying high level of lipid rafts.

Anne Buffière et al.PubMed ↗Publisher ↗

No numbers read from the abstract.